13 results about "Primary sequence" patented technology

Provided is double-stranded RNA which inhibits the infection by RSV-B. Double-stranded RNA that is disclosed herein has a first strand and a second strand that is complementary to the first strand. The first strand has: a main sequence which comprises 19-23 bases and in which a base at the 5'-end is guanine (G) or cytosine (C); and an additional sequence which is added to the 3'-end side of the main sequence and comprises 2-4 bases. The main sequence includes a portion of a nucleotide sequence encoding a fusion protein of RSV-B, wherein the portion is at least a portion of a nucleotide sequence encoding a signal peptide region of the fusion protein.

The invention relates to the technical field of polypeptide drugs, and provides a synthesis method of abparatide, which comprises the following steps: by taking Rink Amide AM resin, Rink MBHA resin or Rink Amide resin as a solid-phase carrier, sequentially coupling single amino acid and 19-21 tripeptide fragments or 19-22 tetrapeptide fragments from N terminal to C terminal through a solid-phase synthesis method according to a primary sequence of abparatide, so as to obtain abparatide peptide resin; the abparatide peptide resin is cracked to obtain abparatide, and a coupling agent / alkali adopted for coupling is selected from at least one of Oxyma / DIC, COMU / DIEA, COMU / TMP, PyOxim / DIEA and TPTU / DIEA. The abparatide crude peptide synthesized by the method disclosed by the invention is high in yield and high in purity, and the synthesis method disclosed by the invention shortens the production time, reduces the production cost and is beneficial to commercial production.

A double-stranded RNA disclosed herein has a first strand and a second strand. The first strand has a main sequence comprising 19-23 bases in which the base at the 5' end is guanine (G) or cytosine (C), and an additional sequence comprising 2-4 bases added to the 3' end side of the main sequence. In addition, the main sequence is determined from a base sequence encoding an RSV L protein and comprises any of the following base sequences: CUUGUUAAGCAGUUUGAGU (SEQ ID NO: 1); CAGUUUGAGUAUGUUAAGA (SEQ ID NO: 2); GUUAAGAGGUGCCUUUAUA (SEQ ID NO: 3).

A method for combining restrictive proteolysis and immunoassays to specifically detect and quantify amyloid-genic XFLC in a biological fluid. This method is accomplished by the use of mAbs that enable the detection and quantification of neoepitopes on dLCCD biomarkers produced after restricted proteolysis of ZFLC, which is very advantageous for kinetically unstable or amyloid-genic LFLC. The methods do not depend on FLC primary sequences in variable and constant domains, and can be used to detect and quantify up to 99% of human XFLC. The clinical utility of the assay includes early detection in individuals suspected of having plasma cell disorders (MGUS, SMM, MM, IgM-AL and AL), differentiation from other amyloidosis such as ATTR, use in companion diagnosis, proving of target conjugation, assessment of treatment response, detection of MRD, detection of recurrence. Assays, such as MSD, lateral flow, mass spectrometry, are also implemented that quantify the resulting dLCCD biomarkers and / or can further increase assay sensitivity.

Double-stranded RNA disclosed herein has a first strand and a second strand. The first strand has a main sequence comprising 19-23 bases in which the base at the 5' end is guanine (G) or cytosine (C), and an additional sequence comprising 2-4 bases added to the 3' end side of the main sequence. In addition, the main sequence comprises any one of the following base sequences:　GAAUGCUUCACACAUUAGU (SEQ ID NO: 3), GCUUCACACAUUAGUAGUA (SEQ ID NO: 4), and GAGUGCAGGACCUACAUCU (SEQ ID NO: 6).

Double-stranded RNA disclosed herein has a first strand and a second strand. The first strand has a main sequence formed from 19-23 bases and having a 5'-end base of guanine (G) or cytosine (C), and the second strand has a complementary main sequence which binds to the main sequence of the first strand. The main sequence of the first strand includes at least a part of a base sequence which is a part of a base sequence encoding a lipocalin-type prostaglandin D synthase, and which encodes a signal peptide region of said lipocalin-type prostaglandin D synthase.

The present disclosure provides a technique for suppressing the proliferation of cells. A double-stranded RNA disclosed herein comprises a first strand and a second strand. The first strand comprises a main sequence comprising 19-23 bases. The second strand comprises a complementary sequence that complementarily binds to the main sequence. The main sequence is a part of the nucleotide sequence encoding prosaposin and comprises the nucleotide sequence represented by SEQ ID NO: 1.

The invention discloses a targeted sequencing method for pathogenic microorganisms, and belongs to the technical field of gene detection.The targeted sequencing method comprises the following steps that free nucleic acid in a to-be-detected sample is extracted and subjected to fragmentation treatment, a targeted sequence of the pathogenic microorganisms is specifically captured after a library is constructed, then the captured sequence is enriched with magnetic beads, and a target sequence is obtained; eluting the enriched product, and removing a sequence which is not specifically bound; amplifying the obtained specific capture sequence by using a universal primer to obtain an amplification product; and sequencing the amplification product on a machine, and removing a host sequence by a bioinformatics analysis method to obtain gene information of the pathogenic microorganisms. According to the method, the pathogen detection sensitivity of a sample in which pathogenic microorganisms mainly exist in the form of free nucleic acid is improved, the sequencing data volume is effectively reduced, and the method has relatively high application value on pathogen detection of samples in which microorganisms such as blood and cerebrospinal fluid exist in the form of free nucleic acid.

Provided is a computer implemented method for mapping transgene integration into n organism by providing a custom genome comprising a reference genome sequence and a transgene sequence, aligning sequence reads of the transgenic organism to the custom genome, identifying candidate junction reads, wherein the candidate junction reads correspond to sequence reads comprising sequence regions that align to the transgene sequence and to the host sequence, categorizing the candidate junction reads into junction clusters, wherein each of the junction clusters comprises a plurality of the candidate junction reads each with an alignment segment terminus within a cluster proximity region of the custom genome, determining a transgene junction based on the junction clusters that possesses at least three of the candidate junction reads within the cluster proximity region of the custom genome and mapping the integration of the transgene into the transgenic organism based on the transgene junctions.

The present disclosure provides double-stranded RNA that can be used in treatment of at least one type of disease. Double-stranded RNA disclosed herein includes a first strand and a second strand. The first strand includes a main sequence. The second strand includes a complementary sequence that complementarily binds to the main sequence. The main sequence comprises any of the base sequences represented by SEQ ID NO: 1-5.

Double-stranded RNA disclosed herein comprises a first strand and a second strand. The first strand has a main sequence. In addition, the main sequence is determined from a base sequence encoding the N protein of respiratory syncytial virus and is composed of any of the following base sequences: CCAGAAUACAGGCAUGACU (SEQ ID NO: 1); CAGGCAUGACUCUCCUGAU (SEQ ID NO: 2); GCAUGACUCUCCUGAUUGU (SEQ ID NO: 3); CUCCUGAUUGUGGGAUGAU (SEQ ID NO: 4); CCUGAUUGUGGGAUGAUAA (SEQ ID NO: 5); GAUUGUGGGAUGAUAAUAU (SEQ ID NO: 6); GAUGAUAAUAUUAUGUAUA (SEQ ID NO: 7); or CAUUAGUAAUAACCAAAUU (SEQ ID NO: 8).

The present disclosure provides double-stranded RNA that can be used in the treatment of at least one type of disease. The double-stranded RNA disclosed herein includes a first strand and a second strand. The first strand includes a main sequence. The second strand includes a complementary sequence that complementarily binds to the main sequence. The main sequence comprises a nucleotide sequence composed of 19-23 nucleotides in which a nucleotide at the 5'-end is guanine or cytosine. At least two of five nucleotides located on the 3'-end side of the main sequence are adenine and uracil. The main sequence comprises a part of a nucleotide sequence constituting mRNA of HSD17B13 and includes at least a part of a nucleotide sequence encoding a signal peptide region of HSD17B13.

A polypeptide target spot prediction method based on sequence and structural characteristics relates to the cross technical field of bioinformatics, artificial intelligence and biomedical engineering, and mainly comprises the following steps: obtaining primary sequence representation of polypeptide and a target spot and physicochemical property representation of residue level; obtaining a three-dimensional space map structure expression of the polypeptide and the target spot; constructing a neural network model for predicting the polypeptide target spot; carrying out supervised training on the model by utilizing labeled polypeptide-target interaction data; model training hyper-parameters are adjusted, the model with the minimum loss function value is selected as an optimal model, and the optimal model is used for predicting unknown polypeptide and target spots. The invention provides a deep learning method which can fully fuse the sequence characteristics and structural characteristics of the polypeptide and the target protein and perform targeted design aiming at the interaction mechanism of the polypeptide and the target protein, realizes efficient and accurate prediction of the polypeptide target, and can be applied to research and development of polypeptide drugs.